NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,802.40+₹41.40 (+2.35%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.96% below the high.
Loading market information…
NSE · ONESOURCE.NS · INR
Stock price, earnings
Quote as of Oct 30, 2026, 08:08 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Onesource Specialty Pharma Ltd.’s quoted price sits in the lower half of its reported 52-week range, 29.88% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Onesource Specialty Pharma Ltd.’s next earnings report is currently expected on Jan 22, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Onesource Specialty Pharma Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
OneSource Specialty Pharma Limited is a biopharmaceutical company focused on the discovery, advancement, production, and market introduction of biological drug products, primarily offered in diverse injectable formulations. The company conducts its operations internationally, with a footprint in India, Ireland, and the United States. It delivers comprehensive contract development and manufacturing (CDMO) services for biologics, encompassing all phases from preclinical and clinical development to commercial-scale supply. Its offerings extend to integrated drug-device systems such as pre-filled syringes, various pen injectors (including dial, push, and pull-push types for both variable and fixed doses), and autoinjectors. Furthermore, OneSource Specialty Pharma manufactures sterile injectable drugs and soft gelatin capsules, and provides specialized biologics solutions tailored for microbial and mammalian cell-line biopharmaceuticals, as well as for cell, gene, and RNA therapies. Established in 2007, the company, headquartered in Bengaluru, India, was formerly known as Stelis Biopharma Limited until its rebranding in February 2024.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Aug 4, 2025 |
| ₹0.20 |
| ₹3.27B-17.15% vs estimate |
| Q4 2024 | May 5, 2025 | ₹8.70-3.33% vs estimate | ₹4.26B0.0% vs estimate |
|---|
| Q3 2024 | Jan 29, 2025 | -₹6.00 | ₹3.93B |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,802.40+₹41.40 (+2.35%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the lower half of its reported 52-week range, 11.96% below the high.
₹9,736.00+₹72.00 (+0.75%)
Divi's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 1.12% below the high.
₹351.65-₹0.25 (-0.07%)
Biocon Limited’s quoted price sits in the lower half of its reported 52-week range, 21.36% below the high.
₹3,094.30+₹19.80 (+0.64%)
Gland Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 2.42% below the high.
₹407.15+₹8.55 (+2.15%)
Syngene International Limited’s quoted price sits in the lower half of its reported 52-week range, 40.03% below the high.
₹1,250.10+₹19.50 (+1.58%)
Concord Biotech Limited’s quoted price sits in the lower half of its reported 52-week range, 22.59% below the high.
₹507.10+₹3.55 (+0.71%)
Blue Jet Healthcare Limited’s quoted price sits in the upper half of its reported 52-week range, 26.35% below the high.
₹146.26-₹3.16 (-2.11%)
Dishman Carbogen Amcis Limited’s quoted price sits in the lower half of its reported 52-week range, 51.73% below the high.
